Argus Research Maintains Buy on Amgen, Raises Price Target to $400
Amgen Inc. +0.32% Pre
Amgen Inc. AMGN | 350.95 350.95 | +0.32% 0.00% Pre |
Argus Research analyst Jasper Hellweg maintains Amgen (NASDAQ:
AMGN) with a Buy and raises the price target from $360 to $400.
